AU6169894A - Methods for treating amyotrophic lateral sclerosis with cntf - Google Patents

Methods for treating amyotrophic lateral sclerosis with cntf

Info

Publication number
AU6169894A
AU6169894A AU61698/94A AU6169894A AU6169894A AU 6169894 A AU6169894 A AU 6169894A AU 61698/94 A AU61698/94 A AU 61698/94A AU 6169894 A AU6169894 A AU 6169894A AU 6169894 A AU6169894 A AU 6169894A
Authority
AU
Australia
Prior art keywords
cntf
day
als
patients
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61698/94A
Other languages
English (en)
Inventor
Frank Collins
Mark Dietz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex Synergen Neuroscience Joint Venture
Original Assignee
Syntex USA LLC
Syntex Synergen Neuroscience Joint Venture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC, Syntex Synergen Neuroscience Joint Venture filed Critical Syntex USA LLC
Publication of AU6169894A publication Critical patent/AU6169894A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU61698/94A 1993-02-08 1994-02-03 Methods for treating amyotrophic lateral sclerosis with cntf Abandoned AU6169894A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1521893A 1993-02-08 1993-02-08
US015218 1993-02-08
US11644093A 1993-09-03 1993-09-03
US116440 1993-09-03
PCT/US1994/001227 WO1994017818A1 (fr) 1993-02-08 1994-02-03 Procedes permettant le traitement de la sclerose laterale amyotrophique avec le cntf

Publications (1)

Publication Number Publication Date
AU6169894A true AU6169894A (en) 1994-08-29

Family

ID=26687105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61698/94A Abandoned AU6169894A (en) 1993-02-08 1994-02-03 Methods for treating amyotrophic lateral sclerosis with cntf

Country Status (4)

Country Link
EP (1) EP0682525A1 (fr)
AU (1) AU6169894A (fr)
CA (1) CA2155540A1 (fr)
WO (1) WO1994017818A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721869B2 (en) * 1995-05-12 2000-07-13 Brigham And Women's Hospital Treatment of alzheimer disease by modulation of synapsins
WO1997012635A1 (fr) * 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Procede de traitement de la sclerose laterale amyotrophique
AU8021098A (en) * 1997-06-13 1998-12-30 Roche Diagnostics Gmbh Improvement of the regeneration of myelin sheaths
AU2001280566A1 (en) * 2000-07-14 2002-01-30 Children's Medical Center Corporation A trophic factor capable of producing a neurosalutary effect in a subject
PL2558499T3 (pl) 2010-04-16 2017-10-31 Biogen Ma Inc Przeciwciała anty-VLA-4
EP3800999A4 (fr) 2018-06-04 2022-06-01 Biogen MA Inc. Anticorps anti-vla-4 ayant une fonction effectrice réduite

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5011914A (en) * 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
CA2155540A1 (fr) 1994-08-18
EP0682525A1 (fr) 1995-11-22
WO1994017818A1 (fr) 1994-08-18

Similar Documents

Publication Publication Date Title
EP0639079B1 (fr) Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
EP2054050B1 (fr) Traitement d'affections de cartilage avec du fgf-18
US9289493B2 (en) Method for treating inflammatory conditions with mucosally administered interleukin-2
TW201704469A (zh) 用於治療cln2疾病之tpp1調配物及方法
KR20170004814A (ko) 헌터증후군 치료제
CN109069595A (zh) 标靶医疗性溶酶体酵素融合蛋白质、其相关调配物与用途
AU6169894A (en) Methods for treating amyotrophic lateral sclerosis with cntf
KR0137361B1 (ko) Gm-csf를 포함하는 백혈구 기능장애 치료조성물
US7232797B2 (en) Erythropoietin dosing regimen for treating anemia
Tsao et al. The childhood muscular dystrophies: making order out of chaos
WO2021081395A1 (fr) Méthodes de traitement de patients présentant des mutations de cfh avec des protéines de cfh de recombinaison
US20220362219A1 (en) Retina regeneration through epigenetics manipulation
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
EP3685850A1 (fr) Composition pharmaceutique liquide contenant du tériparatide présentant d'excellentes propriétés pharmacodynamiques et/ou de stabilité
AU754982B2 (en) Compositions for promoting nerve regeneration
JP2019525931A (ja) ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
JPH03190823A (ja) エリスロポエチン皮下又は筋肉投与剤
RU2804764C2 (ru) Композиции и способы их применения для лечения амиотрофического латерального склероза (als)
JP7350019B2 (ja) 筋萎縮性側索硬化症（ａｌｓ）を治療するための組成物、及び治療のためにそれを使用する方法
KR20230142502A (ko) 골관절염 통증 치료를 위한 link-tsg6의 용도
EP3579865B1 (fr) Compositions thérapeutiques
US5691313A (en) Methods of treating impotency with ciliary neurotrophic factor
CN118440159A (zh) 一种预防或治疗心肌缺血再灌注损伤的多肽及其应用
Mendell et al. Plasma exchange and prednisone in acute inflammatory polyradiculoneuropathy: a controlled randomized trial
WO2019032469A1 (fr) Traitement du surpoids et de l'obésité associés à une déficience en leptine